Latest data from KEYNOTE 42: Pembrolizumab vs chemotherapy in treatment-naive patients (pts) with PD-L1 advanced NSCLC

Bookmark and Share
Published: 18 Apr 2019
Views: 2796
Rating:
Save
Prof Tony Mok - Chinese University of Hong Kong, Hong Kong

Prof Tony Mok speaks to ecancer at the European Lung Cancer Congress 2019 about the Phase 3 KEYNOTE-042 trial of pembrolizumab (MK-3475) versus platinum doublet chemotherapy in treatment-naive patients (pts) with PD-L1–positive advanced non-small cell lung cancer (NSCLC).

Prof Mok emphasises that the importance of KEYNOTE-42 is that it will support the efficacy of patients over 50% PD-L1 expression, and also to see if there is an over-survival benefit at the 1% PD-L1 expression cutoff.

He outlines the data so far, and what this means for the use of single agent pembrolizumab for the 1-49% subgroup as a first line therapy, and the small group of patients that might be applicable for this treatment as opposed to the alternative KEYNOTE-189 regimen.